FOP is caused by a mutation in a gene called “ACVR1” which encodes for the receptor protein “ACVR1/ALK2”. In healthy individuals, a protein called Activin A usually turns this receptor “off”. However, in FOP, Activin A turns the mutant receptor “on”, resulting in the abnormal bone growth (Heterotopic Ossification, HO) that is characteristic of FOP. REGN2477 (also known as garetosmab) is an antibody that binds (ie. holds onto) to Activin A, and blocks its activity. By binding and blocking Activin A, REN2477 may prevent the formation and stop the growth of HO in FOP. REGN2477 has received Orphan Drug status for FOP from the U.S. Food and Drug Administration (FDA), and orphan status for the treatment of FOP in the EU.
About the Clinical Trial
The REGN2477
trial is a global, multi-center,
-controlled trial. Approximately 40 adults 18 years of age or older with the classic FOP mutation (R206H) will be enrolled. The trial is designed to evaluate the safety of REGN2477, and whether monthly dosing will reduce the formation of new HO and reduce the signs and symptoms of flare-ups.
Eligibility Criteria*
- AGE: ≥ 18
- DISEASE ACTIVITY: Participants need to have had FOP disease activity within one year of the screening visit.
- MUTATIONS: R206H
Study Design*
- STUDY TYPE: Interventional
- RANDOMIZED STUDY: Yes
- PLACEBO-CONTROLLED: Yes: for the first 6 months, participants will be given either REGN2477 (50% of participants) or
Placebo(50% of participants). At the end of that period, all participants (100%) will receive REGN2477.Placebo (control): An inactive product that resembles the test medicine or procedure, but without a treatment value. A placebo can be a pill, a powder, or a solution that resembles the test drug, but has no physical effect.
- LENGTH OF PARTICIPATION: 80 weeks
Status
Therapy Approach
Blocking Antibody
Study Sponsor
Regeneron Pharmaceuticals
FAQs
Who is eligible to participate in Regeneron’s
Can children participate in the Regeneron
The current trial is not open to individuals with FOP under the age of 18. Many treatments are first studied in adults to establish the therapy’s safety profile before studying in children.
How many people can participate in the trial?
Approximately 40 people will be enrolled.
Half or up to 20 people will randomly be given the REGN2477 drug and half will be given
Can I participate in LUMINA-1 if I am currently enrolled in the FOP Registry?
Yes. If you are currently in the IFOPA registry, you may be able to also participate in the LUMINA-1 trial, as long as you meet the trial’s eligibility criteria.
This trial is a two-period study design consisting of a 6-month
What centers and locations will be involved in the REGN2477 trial?
Regeneron is currently in the process of identifying further centers to participate in the Phase 2 study. Please refer to Clinicaltrials.gov for the latest information on clinical sites.
How is REGN2477 given to people with FOP?
REGN2477 is taken by IV infusion (i.e. given through the vein) every 4 weeks.
The safety of REGN2477 has been studied in healthy volunteers who do not have FOP. The
What are the travel commitments and requirements to participate in the trial?
Regeneron has hired a specialty travel agency to assist with arrangements for patients and caregivers. Individuals who participate in the REGN2477 trial will receive further information about their travel commitments and study reimbursement.
Who do I contact if I’m interested in learning more about Regeneron’s trial?
Have your doctor connect with Regeneron through one of the resources below:
Medical Information Hotline:
United States: 1-844-MID-REGN (1-844-643-7346)
International: +1-510-496-3637
Email: [email protected]
*For the complete list of eligibility criteria and details on this study, visit ClinicalTrials.gov and use NCT03188666.
Participating Clinical Sites
Mayo Clinic
Rochester, Minnesota, United States, 55905
Contact: Robert Pignolo
Principal Investigator: Robert Pignolo, MD, PhD
Istituto Giannina, Department of Pediatrics
Genova, Liguria, Italy, 16148
Contact: Maja Di Rocco, MD
Principal Investigator: Maja Di Rocco, MD
VU University Medical Center Amsterdam
The Netherlands, 1081 HV
Contact: Marelise Eekhoff, MD, PhD
Principal Investigator: Marelise Eekhoff, MD, PhD
Royal National Orthopaedic Hospital, Brockely Hill Stanmore
United Kingdom, HA7 4LP
Contact: Richard Keen, MD, Jackie Vinton
Principal Investigator: Richard Keen, MD
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Contact: Katherine S. Toder, CCRC
Principal Investigator: Mona Al Mukaddam, MD, MS
Vanderbilt University
Nashville, Tennessee, United States, 37240
Principal Investigator: Katherin Dahir, MD
University of Rzeszow Poland
Rzeszow, Poland, 35-301
Contact: Arthur Mazur, MD
Principal Investigator: Arthur Mazur, MD
Hospital Universitario Ramon y Cajal
Madrid, Spain, 28034
Contact: Javier Bachiller, MD
Principal Investigator: Javier Bachiller,MD
Toronto General Hospital Toronto
Ontario, Canada, M5G 2C4
Contact: Angela Cheung, MD, PhD
Principal Investigator: Angela Cheung MD, PhD
Hopital Cochin
Paris, France, 75014
Contact: Christian Roux, MD
Principal Investigator: Christian Roux, MD
Hopital Lariboisiere, Hospitalier Universitaire Nord
Paris, France, 75010
Contact: Philippe Orcel, MD
Principal Investigator: Philippe Orcel, MD
The IFOPA does not endorse nor recommend specific clinical trials. Please speak with your doctor if you are interested in participating in a clinical trial.
